Does the media favor MRK or SMMT?

In the previous week, Merck & Co., Inc. had 88 more articles in the media than Summit Therapeutics. MarketBeat recorded 97 mentions for Merck & Co., Inc. and 9 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.37 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 45 Very Positive mention(s) 12 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 6 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LPA or SMMT?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Logistic Properties of the Americas $50.13M 2.01 $10.50M N/A N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is SMMT or RVMD more profitable?

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Revolution Medicines N/A -88.20% -57.85%

Does the media favor SMMT or RVMD?

In the previous week, Revolution Medicines had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Revolution Medicines and 9 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.37 beat Summit Therapeutics' score of 0.37 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is SMMT or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Summit Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Biogen 8.32% 11.18% 6.88%

Does the media prefer SMMT or BIIB?

In the previous week, Biogen had 19 more articles in the media than Summit Therapeutics. MarketBeat recorded 28 mentions for Biogen and 9 mentions for Summit Therapeutics. Biogen's average media sentiment score of 1.35 beat Summit Therapeutics' score of 0.37 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMMT or ALNY?

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Summit Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 9 mentions for Summit Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Summit Therapeutics' score of 0.37 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Summit Therapeutics (SMMT) Competitors

$13.16 +0.73 (+5.87%)

As of 08/21/2026 04:00 PM Eastern

Compare

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

Should you buy Summit Therapeutics stock or one of its competitors? Summit Therapeutics's main competitors and comparable companies include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size.

How does Summit Therapeutics compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

In the previous week, Merck & Co., Inc. had 88 more articles in the media than Summit Therapeutics. MarketBeat recorded 97 mentions for Merck & Co., Inc. and 9 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.37 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	45 Very Positive mention(s)	12 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	6 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Merck & Co., Inc. has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

Merck & Co., Inc. presently has a consensus target price of $144.10, suggesting a potential downside of 5.46%. Summit Therapeutics has a consensus target price of $24.25, suggesting a potential upside of 84.24%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	5.78	$18.25B	$1.25	121.94
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Merck & Co., Inc. has a net margin of 4.77% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 16.73% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Logistic Properties of the Americas (NYSEAMERICAN:LPA) and Summit Therapeutics (NASDAQ:SMMT) are related companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Logistic Properties of the Americas	$50.13M	2.01	$10.50M	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Logistic Properties of the Americas has a beta of 5.38, meaning that its stock price is 438% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

42.7% of Logistic Properties of the Americas shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 32.0% of Logistic Properties of the Americas shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Logistic Properties of the Americas has a net margin of 30.97% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 0.46% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Logistic Properties of the Americas	30.97%	0.46%	0.21%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Summit Therapeutics had 8 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 9 mentions for Summit Therapeutics and 1 mentions for Logistic Properties of the Americas. Logistic Properties of the Americas' average media sentiment score of 1.24 beat Summit Therapeutics' score of 0.37 indicating that Logistic Properties of the Americas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Logistic Properties of the Americas	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Logistic Properties of the Americas currently has a consensus price target of $7.50, suggesting a potential upside of 135.11%. Summit Therapeutics has a consensus price target of $24.25, suggesting a potential upside of 84.24%. Given Logistic Properties of the Americas' higher possible upside, equities research analysts clearly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Summit Therapeutics (NASDAQ:SMMT) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Summit Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 84.24%. Revolution Medicines has a consensus price target of $167.89, suggesting a potential downside of 19.85%. Given Summit Therapeutics' higher probable upside, equities analysts clearly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Summit Therapeutics has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Revolution Medicines	N/A	-88.20%	-57.85%

In the previous week, Revolution Medicines had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Revolution Medicines and 9 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.37 beat Summit Therapeutics' score of 0.37 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Revolution Medicines beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Summit Therapeutics compare to Biogen?

Summit Therapeutics (NASDAQ:SMMT) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Summit Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37

Biogen has a net margin of 8.32% compared to Summit Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 19 more articles in the media than Summit Therapeutics. MarketBeat recorded 28 mentions for Biogen and 9 mentions for Summit Therapeutics. Biogen's average media sentiment score of 1.35 beat Summit Therapeutics' score of 0.37 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summit Therapeutics currently has a consensus target price of $24.25, suggesting a potential upside of 84.24%. Biogen has a consensus target price of $227.07, suggesting a potential upside of 4.75%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Biogen beats Summit Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Summit Therapeutics (NASDAQ:SMMT) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Summit Therapeutics presently has a consensus price target of $24.25, suggesting a potential upside of 84.24%. Alnylam Pharmaceuticals has a consensus price target of $386.62, suggesting a potential upside of 63.67%. Given Summit Therapeutics' higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96

Alnylam Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Summit Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 9 mentions for Summit Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 0.81 beat Summit Therapeutics' score of 0.37 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Summit Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Summit Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.50B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-11.75	11.62	272.60	24.25
Price / Sales	N/A	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	16.66	16.80	13.05	6.20
Net Income	-$1.08B	-$12.50M	$3.47B	$348.59M
7 Day Performance	-1.42%	3.29%	2.09%	0.08%
1 Month Performance	-12.15%	8.23%	6.64%	3.88%
1 Year Performance	-49.77%	55.05%	25.02%	16.98%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	3.7669 of 5 stars	$13.16 +5.9%	$24.25 +84.2%	-49.8%	$10.50B	N/A	N/A	110	Analyst Forecast Gap Up
MRK Merck & Co., Inc.	4.2177 of 5 stars	$135.78 +0.2%	$135.50 -0.2%	+74.8%	$334.43B	$65.01B	108.62	75,000	Trending News Analyst Downgrade Options Volume
LPA Logistic Properties of the Americas	4.4177 of 5 stars	$3.28 -0.6%	$7.50 +128.7%	-52.6%	$104.34M	$50.13M	6.07	30	Gap Down
RVMD Revolution Medicines	2.5369 of 5 stars	$203.71 +0.8%	$161.79 -20.6%	+466.0%	$43.30B	$11.58M	N/A	250	Positive News Analyst Forecast
BIIB Biogen	3.9582 of 5 stars	$209.83 -0.4%	$227.07 +8.2%	+55.6%	$31.12B	$9.89B	37.14	7,500	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to Biogen?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, BIIB, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Does the media favor MRK or SMMT?

Which has more volatility and risk, MRK or SMMT?

Do analysts recommend MRK or SMMT?

Which has stronger earnings & valuation, MRK or SMMT?

Do insiders & institutionals hold more shares of MRK or SMMT?

Is MRK or SMMT more profitable?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Which has better earnings & valuation, LPA or SMMT?

Which has more risk and volatility, LPA or SMMT?

Do insiders and institutionals have more ownership in LPA or SMMT?

Is LPA or SMMT more profitable?

Does the media prefer LPA or SMMT?

Do analysts recommend LPA or SMMT?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Do analysts rate SMMT or RVMD?

Which has more volatility and risk, SMMT or RVMD?

Which has stronger earnings & valuation, SMMT or RVMD?

Is SMMT or RVMD more profitable?

Does the media favor SMMT or RVMD?

Do institutionals and insiders hold more shares of SMMT or RVMD?

Summary

How does Summit Therapeutics compare to Biogen?

Which has more volatility & risk, SMMT or BIIB?

Which has better earnings and valuation, SMMT or BIIB?

Is SMMT or BIIB more profitable?

Does the media prefer SMMT or BIIB?

Do institutionals and insiders hold more shares of SMMT or BIIB?

Do analysts recommend SMMT or BIIB?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts prefer SMMT or ALNY?

Which has preferable earnings and valuation, SMMT or ALNY?

Does the media favor SMMT or ALNY?

Do insiders and institutionals have more ownership in SMMT or ALNY?

Which has more volatility & risk, SMMT or ALNY?

Is SMMT or ALNY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools